Vanguard Asset Management
CSTL icon

Vanguard Asset Management’s Castle Biosciences CSTL Stock Holding History

Vanguard Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$421K Hold
17,653
– – ﹤0.01% 2250
2026
Q1 		$433K Buy
+17,653
New +$578K ﹤0.01% 2156

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Vanguard Asset Management's CSTL Position: Q2 2026 in Review

Vanguard Asset Management held its Castle Biosciences (CSTL) position steady in Q2 2026 at 17,653 shares worth $421K. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Vanguard Asset Management first reported a position in CSTL in Q1 2026 and has held it in 2 quarters since. The position peaked at $433K in Q1 2026. 167 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Vanguard Asset Management held 17,653 shares of Castle Biosciences worth $421K as of Q2 2026.
  • Vanguard Asset Management left its Castle Biosciences share count unchanged in Q2 2026.
  • Castle Biosciences made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2250 holding.
  • Vanguard Asset Management first reported a position in Castle Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's Castle Biosciences position peaked at $433K in Q1 2026.
  • 167 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.